Company
Every investor coverage indicates participated in a round Neuralink raised.
Companies Neuralink acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Neuralink. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
An analysis of what happens to brain-implant trial participants once studies end, covering Australia's growing neurotech sector, EpiMinder's FDA approval, Synchron's funding, and recommendations from a convened panel of specialists.
Roundup of eight funding deals: Synchron's Series D, plus raises by Lumonus AI, Hullbot, Nbryo, Cytophenix, Giftbee, Understanding Zoe and Zeligate, spanning medtech, robotics, agtech and AI.
Also Startup Daily·Startup Daily·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily
Auckland venture firm NZVC plans a second fund backing 50-60 Australia-NZ founders and has already invested in an Australian robotics startup and two New Zealand companies.
A rundown of Gartner's ten technology trends to watch in 2025, spanning agentic AI, governance platforms, disinformation security, quantum-safe cryptography, spatial computing, robotics and neurological enhancement, with Australian startup Synchron cited.
Australian neurotech firm Synchron reported year-long trial results showing its brain implant was safe in six US patients, including one who used Amazon's Alexa by thought alone, keeping it ahead of Musk's Neuralink.
Analysis of Neuralink's first human implant, its clinical and ethical challenges, and the competitive threat posed by Melbourne brain-computer interface startup Synchron.
An overview of brain-computer interface history and current clinical-trial leaders, profiling BrainGate, a Dutch medical centre, and Melbourne-founded Synchron, written by a University of Melbourne neural engineering academic.
Analysis of the technological singularity concept, covering brain-computer interface work by Neuralink and Synchron, expert predictions about artificial general intelligence, and worries over unregulated AI. Republished from The Conversation.
Brain-computer interface maker Synchron has closed an oversubscribed Series C, with proceeds earmarked for product development and clinical trials; its co-founder downplays any rivalry with Neuralink.
Also Startup Daily·SmartCompany·@AuManufacturing·Techboard·Startup Daily